Savara Inc SEC filings SVRA
Savara Inc has 1,000 filings in SEC EDGAR's recent list, going back to Jul 22, 2009. Its latest annual report, Form ARS, was filed on Apr 24, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Jun 8, 2026 (officer or director change, bylaw or fiscal year change, shareholder vote results). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | May 21, 2024 | — |
| CORRESP | Letter to the SEC | May 20, 2024 | — |
| UPLOAD | Letter from the SEC | May 14, 2024 | — |
| EFFECT | Filing | Jul 16, 2021 | — |
| CORRESP | Letter to the SEC | Jul 14, 2021 | — |
| UPLOAD | Letter from the SEC | Jul 12, 2021 | — |
| EFFECT | Filing | Apr 29, 2020 | — |
| CORRESP | Letter to the SEC | Apr 27, 2020 | — |
| UPLOAD | Letter from the SEC | Apr 24, 2020 | — |
| D | Filing | Jan 2, 2020 | — |
| CT ORDER | Filing | Aug 30, 2018 | — |
| EFFECT | Filing | Jul 13, 2018 | — |
| CORRESP | Letter to the SEC | Jul 10, 2018 | — |
| UPLOAD | Letter from the SEC | Jul 9, 2018 | — |
| CERTNAS | Auto-generated paper document | Apr 27, 2017 | — |
| 25 | Form 25 | Apr 27, 2017 | — |
| 8-A12B | Filing | Apr 27, 2017 | — |
| 425 | 8-k | Apr 25, 2017 | — |
| 425 | Filing | Apr 21, 2017 | — |
| 425 | 8-k | Apr 21, 2017 | — |
| 425 | 8-k | Apr 20, 2017 | — |
| 425 | 8-k | Apr 17, 2017 | — |
| 425 | 8-k | Apr 11, 2017 | — |
| 425 | 8-k | Apr 10, 2017 | — |
| 425 | Filing | Apr 7, 2017 | — |
| 425 | 8-k | Mar 16, 2017 | — |
| EFFECT | Filing | Mar 15, 2017 | — |
| 425 | Filing | Mar 15, 2017 | — |
| CORRESP | Letter to the SEC | Mar 13, 2017 | — |
| CT ORDER | Filing | Mar 13, 2017 | — |
| CORRESP | Letter to the SEC | Mar 10, 2017 | — |
| 425 | Filing | Mar 6, 2017 | — |
| 425 | Current report, items 7.01, 8.01 and 9.01 | Mar 6, 2017 | — |
| UPLOAD | Letter from the SEC | Feb 22, 2017 | — |
| 425 | Current report, items 8.01 and 9.01 | Jan 26, 2017 | — |
| 425 | Current report, item 5.02 | Jan 23, 2017 | — |
| 425 | 8-k item 8.01 | Jan 9, 2017 | — |
| 425 | 8-k | Jan 9, 2017 | — |
| EFFECT | Filing | May 16, 2016 | — |
| EFFECT | Filing | May 16, 2016 | — |
| EFFECT | Filing | Aug 19, 2015 | — |
| CORRESP | Letter to the SEC | Aug 13, 2015 | — |
| UPLOAD | Letter from the SEC | Mar 31, 2015 | — |
| CT ORDER | Filing | May 16, 2014 | — |
| EFFECT | Filing | May 14, 2014 | — |
| D | Filing | Mar 5, 2014 | — |
| EFFECT | Filing | Jun 14, 2013 | — |
| EFFECT | Filing | May 1, 2012 | — |
| EFFECT | Filing | Oct 13, 2011 | — |
| CORRESP | Letter to the SEC | Oct 12, 2011 | — |
| CORRESP | Letter to the SEC | Jun 14, 2011 | — |
| CT ORDER | Filing | Jun 6, 2011 | — |
| UPLOAD | Letter from the SEC | May 31, 2011 | — |
| EFFECT | Filing | May 11, 2011 | — |
| CORRESP | Letter to the SEC | May 11, 2011 | — |
| CORRESP | Letter to the SEC | May 10, 2011 | — |
| CORRESP | Letter to the SEC | Apr 28, 2011 | — |
| UPLOAD | Letter from the SEC | Mar 14, 2011 | — |
| EFFECT | Filing | Apr 1, 2010 | — |
| EFFECT | Filing | Mar 23, 2010 | — |
| EFFECT | Filing | Oct 6, 2009 | — |
Showing 61 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SVRA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Austin, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1160308
- Former names
- Mast Therapeutics, Inc. (until Apr 25, 2017); ADVENTRX PHARMACEUTICALS INC (until Mar 1, 2013); BIOKEYS PHARMACEUTICALS INC (until May 15, 2003)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.